ARTICLE | Clinical News
Roche’s RG6206 becomes second myostatin inhibitor to fail in DMD in past year
November 8, 2019 7:52 PM UTC
Updated on Nov 8, 2019 at 10:15 PM UTC
The failure of Roche’s RG6206 marks another blow to the hypothesis that blocking myostatin can improve muscle growth and function in ambulatory boys with Duchenne muscular dystrophy.
Roche (SIX:ROG; OTCQX:RHHBY) sent a letter Wednesday to the DMD community, including non-profit Parent Project Muscular Dystrophy (PPMD), disclosing that the company was discontinuing development of the anti-MSTN adnectin IgG1-Fc fusion protein after a preplanned interim futility analysis showed RG6206 was unlikely to meet the primary endpoint of an improvement in the North Star Ambulatory Assessment in the Phase II/III SPITFIRE trial...
BCIQ Target Profiles